Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.

Autor: Sargos P; Department of Radiotherapy, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: p.sargos@bordeaux.unicancer.fr., Bellera C; Epicene Team, Bordeaux Population Health Research Center, UMR 1219, Inserm, University of Bordeaux, Bordeaux, France; Clinical and Epidemiological Research Unit, Comprehensive Cancer Center, Inserm CIC1401, Institut Bergonié, Bordeaux, France., Bentahila R; Department of Radiotherapy, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France., Guerni M; Department of Radiotherapy, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France., Benziane-Ouaritini N; Department of Radiotherapy, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France., Teyssonneau D; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Vuong NS; Urology Department, Clinique Saint-Augustin, Bordeaux, France., Ploussard G; Department of Urology UROSUD, La Croix du Sud Hospital, Toulouse, France., Roupret M; GRC 5 Predictive Onco-Urology Research Group and Urology Department, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France., Roubaud G; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 May 15. Date of Electronic Publication: 2024 May 15.